Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

Maria Gabriella Ferrandina; Manuela Ludovisi; Giacomo Corrado; Vito Carone; Vanda Salutari; Marco Petrillo; Giovanni Scambia

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

Maria Gabriella Ferrandina
, Manuela Ludovisi
, Giacomo Corrado
, Vito Carone
, Vanda Salutari
, Marco Petrillo
, Giovanni Scambia

Risultato della ricerca: Contributo in rivista › Articolo › peer review

Lingua originale	Inglese
pagine (da-a)	187-193
Numero di pagine	7
Rivista	Gynecologic Oncology
Stato di pubblicazione	Pubblicato - 2008

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

CA125
Ovarian cancer
prognostic role
response to chemotherapy

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{1970295c85204ce0a3622019b20a57ac,

title = "Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.",

keywords = "CA125, Ovarian cancer, prognostic role, response to chemotherapy, CA125, Ovarian cancer, prognostic role, response to chemotherapy",

author = "Ferrandina, \{Maria Gabriella\} and Manuela Ludovisi and Giacomo Corrado and Vito Carone and Vanda Salutari and Marco Petrillo and Giovanni Scambia",

year = "2008",

language = "English",

pages = "187--193",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

}

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. / Ferrandina, Maria Gabriella; Ludovisi, Manuela; Corrado, Giacomo et al.
In: Gynecologic Oncology, 2008, pag. 187-193.

Risultato della ricerca: Contributo in rivista › Articolo › peer review

TY - JOUR

T1 - Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

AU - Ferrandina, Maria Gabriella

AU - Ludovisi, Manuela

AU - Corrado, Giacomo

AU - Carone, Vito

AU - Salutari, Vanda

AU - Petrillo, Marco

AU - Scambia, Giovanni

PY - 2008

Y1 - 2008

KW - CA125

KW - Ovarian cancer

KW - prognostic role

KW - response to chemotherapy

KW - CA125

KW - Ovarian cancer

KW - prognostic role

KW - response to chemotherapy

UR - http://hdl.handle.net/10807/31923

M3 - Article

SN - 0090-8258

SP - 187

EP - 193

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -